Skip to main content
Caplight Logo









Illuminate Therapeutics

Illuminate Therapeutics

Private
PennsylvaniaHealthcare & Life Scienceshttps://illuminatetherapeutics.com

Last Round

Seed

Jun 1, 2025

Total Funding Raised

$75,000

Company Overview

Illuminate Therapeutics is a biotechnology company developing a light-activated drug delivery and release (LADDR) platform for the targeted treatment of oncology and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

light-activated drug deliveryLADDRtargeted therapynanoparticle drug deliveryprecision medicinenucleic acid therapyoncology therapeuticsspatiotemporal drug releasephotodynamic therapydrug delivery platformautoimmune disease treatmentbiotech startupnanomedicinecontrolled release

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Illuminate Therapeutics Comparables

Compare Illuminate Therapeutics with similar companies based on industry and business-model similarity.

Illuminate Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Covalt Bio
93%
GenLumina
84%
LightOx Ltd
73%

Illuminate Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJun 1, 2025
GrantApr 29, 2022

Illuminate Therapeutics Investors

Notable investors and investment history

Illuminate Therapeutics investors
InvestorRounds
General InceptionSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2025

    Raised Seed round with General Inception as an investor.

  • Apr 29, 2022

    $75K grant round closed.

Illuminate Therapeutics Filings

Explore SEC and related filing metadata, where available.

Illuminate Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Illuminate Therapeutics's valuation, stock price, and market status.

Is Illuminate Therapeutics a public or private company?

Illuminate Therapeutics is a private company.

What is the current stock price of Illuminate Therapeutics?

Illuminate Therapeutics is a private company with no public stock price. Caplight tracks Illuminate Therapeutics's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is Illuminate Therapeutics worth (valuation)?

Valuation information for Illuminate Therapeutics is not publicly available.

Can I buy Illuminate Therapeutics stock?

Illuminate Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Illuminate Therapeutics's last funding round?

Illuminate Therapeutics's most recent funding round was Seed on June 1, 2025.

Who are the main investors in Illuminate Therapeutics?

Key investors in Illuminate Therapeutics include General Inception.

Will Illuminate Therapeutics IPO soon?

No public IPO plans have been announced for Illuminate Therapeutics.

How can I track Illuminate Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Illuminate Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPennsylvania
Year Founded2022
Last FundingJun 1, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?